文献速递MDS 与骨髓增殖性肿瘤

芦可替尼停药后骨髓纤维化患者的克隆演化与结局

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
PubMed 文献 · Blood · 2017-07-03

本中心1/2期研究中,中位随访79个月后86例骨髓纤维化患者停用芦可替尼,其中30例在治疗期间死亡。其余56例停药后中位随访32个月,停药后中位生存14个月。62例有分子数据者中22例(35%)在用药期间获得新突变,克隆演化者停药后生存显著更短(6个月 vs 16个月),输血依赖是唯一与克隆演化相关的临床变量。

要点

  • 芦可替尼停药后中位生存仅14个月,克隆演化者生存更短(6个月 vs 16个月)。
  • 用药期间获得新突变者占35%(22/62),其中61%(14例)为ASXL1突变。
  • 开始治疗时血小板<260×10⁹/L或停药时<100×10⁹/L与停药后生存更短相关。

核心结论

  • 芦可替尼停药后骨髓纤维化患者生存期短,克隆演化或用药期间血小板下降可能是预后不良的标志。
  • 作者认为这些发现强调了需要新的治疗方法。

研究设计与样本

  • 本中心开展的1/2期研究,纳入骨髓纤维化患者,分析芦可替尼停药后的结局。
  • 中位随访79个月,86例患者停用芦可替尼,其中30例在治疗期间死亡。
  • 其余56例停药后中位随访32个月,62例患者有基线和随访时的分子数据。

主要发现

  • 停药后中位生存14个月(56例停药后中位随访32个月)。
  • 开始治疗时血小板<260×10⁹/L或停药时血小板<100×10⁹/L与停药后生存更短相关。
  • 62例有分子数据患者中22例(35%)在芦可替尼治疗期间获得新突变,其中14例(61%)为ASXL1突变。
  • 克隆演化者停药后生存显著更短(6个月 vs 16个月)。
  • 输血依赖是唯一与克隆演化相关的临床变量。

临床怎么用

  • 作者认为克隆演化或芦可替尼治疗期间血小板下降可能是预后不良的标志。
  • 作者认为这些发现强调了需要新的治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets <260 × 109/L at the start of therapy or <100 × 109/L at the time of discontinuation were associated with shorter survival after discontinuation. Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in ASXL1). Patients showing clonal evolution had significantly shorter survival after discontinuation (6 vs 16 months). Transfusion dependency was the only clinical variable associated with clonal evolution. These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017. PMID: 28674026. doi:10.1182/blood-2017-05-783225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。